Dr. Migden is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Dermatology, 1998 - 2001- Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 1997 - 1998
University of Utah School of MedicineClass of 1997
Certifications & Licensure
TX State Medical License 2003 - 2025
AZ State Medical License 2000 - 2021
OK State Medical License 2020 - 2021
MN State Medical License 1999 - 2018
FL State Medical License 2001 - 2017
WI State Medical License 2003 - 2017- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
- Fellow (FASDS) American Society for Dermatologic Surgery
Clinical Trials
- Spectral Diagnosis of Cutaneous Malignancy Start of enrollment: 2007 Apr 01
Publications & Presentations
PubMed
- Current and emerging intralesional immunotherapies in cutaneous oncology.Carolyn M Stull, Denise Clark, Tayler Parker, Munir H Idriss, Vishal A Patel
Journal of the American Academy of Dermatology. 2024-11-01 - A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, ...Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults
Journal of the American Academy of Dermatology. 2024-09-07 - 1 citationsTreatments on the horizon for locally advanced basal cell carcinoma.Munir H Idriss, Munir H Idriss, Carolyn M Stull, Michael R Migden
Cancer Letters. 2024-05-01
Journal Articles
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaJade Homsi, Michael R Migden, Nikhil I Khushalani, The New England Journal of Medicine
Lectures
- Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).2019 ASCO Annual Meeting - 6/1/2019
- 42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLT.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Parting Advice on Non-Melanoma Skin Cancer ManagementJuly 22nd, 2019
Clinical Challenges: What’s Next for Cutaneous Squamous Cell Carcinoma?June 15th, 2019
First Treatment Approved for Common Form of Advanced Skin CancerOctober 1st, 2018- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
